MC
ARKG icon

Moors & Cabot’s ARK Genomic Revolution ETF ARKG Stock Holding History

Moors & Cabot’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$376K Sell
8,940
-700
-7% -$22.3K 0.01% 661
2026
Q1 		$255K Buy
+9,640
New +$282K 0.01% 770
2024
Q4 		– Sell
-7,961
Closed -$204K – 888
2024
Q3 		$204K Sell
7,961
-900
-10% -$22.9K 0.01% 796
2024
Q2 		$208K Sell
8,861
-700
-7% -$17.7K 0.01% 755
2024
Q1 		$275K Hold
9,561
– – 0.01% 702
2023
Q4 		$314K Sell
9,561
-1,550
-14% -$42.1K 0.02% 615
2023
Q3 		$310K Sell
11,111
-30
-0.3% -$981 0.02% 591
2023
Q2 		$380K Sell
11,141
-20
-0.2% -$629 0.03% 526
2023
Q1 		$336K Sell
11,161
-400
-3% -$12.4K 0.02% 562
2022
Q4 		$326K Sell
11,561
-850
-7% -$27K 0.02% 554
2022
Q3 		$408K Sell
12,411
-2,411
-16% -$88.5K 0.03% 465
2022
Q2 		$467K Sell
14,822
-1,413
-9% -$49.4K 0.03% 431
2022
Q1 		$746K Sell
16,235
-2,102
-11% -$100K 0.05% 360
2021
Q4 		$1.12M Sell
18,337
-3,782
-17% -$261K 0.07% 259
2021
Q3 		$1.65M Sell
22,119
-5
-0% -$420 0.1% 192
2021
Q2 		$2.05M Buy
22,124
+2,069
+10% +$176K 0.14% 153
2021
Q1 		$1.78M Buy
20,055
+4,250
+27% +$422K 0.14% 155
2020
Q4 		$1.48M Buy
15,805
+5,487
+53% +$437K 0.12% 165
2020
Q3 		$657K Sell
10,318
-2,914
-22% -$171K 0.06% 280
2020
Q2 		$690K Buy
13,232
+4,078
+45% +$175K 0.07% 248
2020
Q1 		$286K Hold
9,154
– – 0.04% 387
2019
Q4 		$308K Buy
9,154
+792
+9% +$25.2K 0.03% 457
2019
Q3 		$248K Buy
8,362
+500
+6% +$16.3K 0.03% 500
2019
Q2 		$270K Buy
+7,862
New +$252K 0.03% 436

Other funds holding ARKG

JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Moors & Cabot's ARKG Position: Q2 2026 in Review

Moors & Cabot reduced its ARK Genomic Revolution ETF (ARKG) stake by 7.3% in Q2 2026, selling an estimated $22.3K and leaving 8,940 shares worth $376K. The position accounts for 0.01% of the portfolio, ranked #661.

Moors & Cabot first reported a position in ARKG in Q2 2019 and has held it in 24 quarters since. The position peaked at $2.05M in Q2 2021. 271 funds tracked by Wall St. Rank hold ARKG as of Q2 2026.

  • Moors & Cabot held 8,940 shares of ARK Genomic Revolution ETF worth $376K as of Q2 2026.
  • Moors & Cabot sold 700 ARK Genomic Revolution ETF shares in Q2 2026, an estimated $22.3K.
  • ARK Genomic Revolution ETF made up 0.01% of Moors & Cabot's portfolio in Q2 2026, its #661 holding.
  • Moors & Cabot first reported a position in ARK Genomic Revolution ETF in Q2 2019 and has held it in 24 quarters since.
  • Moors & Cabot's ARK Genomic Revolution ETF position peaked at $2.05M in Q2 2021.
  • 271 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2026.

Based on Moors & Cabot's 13F filing for Q2 2026, filed 10 Aug 2026.